Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet.

ABSTRACT:

Background

In older patients with overactive bladder (OAB), mirabegron, a β₃-adrenoreceptor agonist, represents an alternative treatment that may have a favorable risk-benefit profile.

Objectives

Our objective was to further examine the safety and tolerability of mirabegron versus placebo treatment in patients aged ≥ 65 years with OAB-wet.

Methods

We conducted a 12-week, double-blind, randomized, placebo-controlled phase IV study to compare mirabegron with placebo. Community-dwelling patients aged ≥ 65 years with OAB-wet (one or more incontinence episode and three or more urgency episodes, and an average of eight or more micturitions/24 h over a 3-day diary) were randomized to receive placebo or mirabegron 25 mg/day (optional dose escalation to 50 mg/day at

SUBMITTER: Herschorn S 

PROVIDER: S-EPMC7473960 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature